Ketamine for Bipolar Depression: Biochemical, Psychotherapeutic, and Psychedelic Approaches

Bipolar disorder type 1 is a serious chronic psychiatric condition often featuring refractory depressive episodes. Racemic ketamine, a glutamate modulator with dissociative and psychedelic properties, has demonstrated rapid antidepressant and anti-obsessional effects that may help treat bipolar depression. Existing research has mostly examined sub-psychedelic doses given by infusion without psychotherapy. This article expands on that work by describing three paradigms for ketamine treatment: biochemical, psychotherapeutic, and psychedelic. The authors use composite clinical vignettes to illustrate different ways of using ketamine for bipolar depression and discuss clinical considerations including route, dose, frequency, chemical mitigators, and adverse events. The paradigms have broad applicability beyond bipolar treatment.

Study at a glance

Abstract

Bipolar disorder (type 1) is a serious and chronic psychiatric illness that can be difficult to treat. Many bipolar patients have refractory depressive episodes. Racemic ketamine, a glutamate modulator with prominent dissociate and psychedelic properties, has been demonstrated to have rapid acting antidepressant and anti-obsessional effects which may be useful for treating the symptoms of bipolar depression. Most of the existing research literature on unipolar and bipolar depression has looked at racemic ketamine in the sub-psychedelic dose range given by infusion as a stand-alone treatment (without concurrent psychotherapy). This article expands on the existing research by articulating three different paradigms for ketamine treatment: biochemical, psychotherapeutic, and psychedelic. The authors use composite clinical vignettes to illustrate different ways of working with ketamine to treat bipolar depression, and discuss a variety of clinical considerations for using ketamine with this population, including route, dose, frequency, chemical mitigators, and adverse events. Note that the conceptual paradigms could be applied to any ketamine treatment, with broad applicability beyond bipolar treatment.